Stock 688217 SHANGHAI RIGHTONGENE BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Rightongene Biotechnology Co., Ltd.

Equities

688217

CNE100005212

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
19.74 CNY -1.25% Intraday chart for Shanghai Rightongene Biotechnology Co., Ltd. -4.68% -44.83%
26/04 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
29/02 Shanghai Rightongene Biotechnology Co., Ltd. commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on February 28, 2024. CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 4,042 1,965 1,999 1,103 - -
Enterprise Value (EV) 1 4,042 1,965 1,999 1,103 1,103 1,103
P/E ratio 79 x 48.4 x 239 x 94 x 79 x 63.7 x
Yield - - - - - -
Capitalization / Revenue - 4.63 x 7.79 x 3.55 x 2.94 x 2.43 x
EV / Revenue - 4.63 x 7.79 x 3.55 x 2.94 x 2.43 x
EV / EBITDA - - - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - 2.1 x 2.11 x 1.15 x 1.14 x 1.12 x
Nbr of stocks (in thousands) 55,577 55,577 55,856 55,856 - -
Reference price 2 72.72 35.35 35.78 19.74 19.74 19.74
Announcement Date 25/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 424.3 256.6 311 375 453
EBITDA - - - - - -
EBIT 1 - 71.71 -7.244 8 11 15
Operating Margin - 16.9% -2.82% 2.57% 2.93% 3.31%
Earnings before Tax (EBT) 1 - 71.48 -9.895 13 15 19
Net income 1 46.01 40.47 8.124 11.56 14.04 17.09
Net margin - 9.54% 3.17% 3.72% 3.74% 3.77%
EPS 2 0.9200 0.7300 0.1500 0.2100 0.2500 0.3100
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 25/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 4.43% 0.86% 1.21% 1.45% 1.73%
ROA (Net income/ Total Assets) - 3.44% 0.76% 1.1% 1.3% 1.4%
Assets 1 - 1,177 1,063 1,051 1,080 1,221
Book Value Per Share 2 - 16.90 16.90 17.10 17.40 17.70
Cash Flow per Share 2 - 1.310 0.8100 1.160 0.7400 1.120
Capex 1 - 107 109 125 125 125
Capex / Sales - 25.12% 42.43% 40.19% 33.33% 27.59%
Announcement Date 25/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Shanghai Rightongene Biotechnology Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19.74
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
SHANGHAI RIGHTONGENE BIOTECHNOLOGY CO., LTD. Stock Shanghai Rightongene Biotechnology Co., Ltd.
-44.83% 15Cr
BIOMÉRIEUX Stock bioMérieux
-11.78% 1.12TCr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-13.76% 729.18Cr
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+29.50% 556.51Cr
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-0.19% 531.31Cr
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-19.19% 368.03Cr
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+7.62% 258.29Cr
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-65.24% 232.83Cr
VITROLIFE AB Stock Vitrolife AB
-10.48% 222.66Cr
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+27.80% 221.38Cr
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 688217 Stock
  4. Financials Shanghai Rightongene Biotechnology Co., Ltd.